Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 842 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Prostate Adenocarcinoma Clear all
Completed Phase 1 Interventional

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

NCT00083213
View directory record Official record
Conditions
Cancer
Interventions
ziv-aflibercept
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Not applicable Interventional Results available

Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost for Clinically Localized Prostate Cancer (RAD 1203)

NCT01856855
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Radiation Toxicity, Sexual Dysfunction
Interventions
Stereotactic Body Radiation Therapy with Integrated Boost
Radiation
Lead sponsor
John Fiveash, MD
Other
Eligibility
19 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 2 Interventional

Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer

NCT00039104
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
rebimastat, zoledronic acid, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Jul 21, 2026, 11:01 AM EDT
Recruiting Phase 3 Interventional

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

NCT06205316
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Recurrent Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions
Antiandrogen Therapy, Biospecimen Collection, Hypofractionated Radiation Therapy, Positron Emission Tomography, Stereotactic Body Radiation Therapy, Survey Administration, Magnetic Resonance Imaging
Drug · Procedure · Radiation + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
6
States / cities
Scottsdale, Arizona • Albert Lea, Minnesota • Mankato, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 21, 2026, 11:01 AM EDT
Active, not recruiting Phase 1 Interventional

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

NCT01480154
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7, Stage III Prostate Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
Interventions
Akt Inhibitor MK2206, Hydroxychloroquine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 1 Interventional

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

NCT02655822
View directory record Official record
Conditions
Renal Cell Cancer, Metastatic Castration Resistant Prostate Cancer
Interventions
Ciforadenant, Ciforadenant + atezolizumab
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
15
States / cities
Tucson, Arizona • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2021 · Synced Jul 21, 2026, 11:01 AM EDT
Terminated Phase 2 Interventional Results available

Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00527124
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage IV Prostate Cancer
Interventions
cediranib maleate, docetaxel, prednisone, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
4
States / cities
Detroit, Michigan • Houston, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 1 Interventional

Fluorescent Imaging of Nerves With Illuminare-1 During Surgery

NCT04983862
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Illuminare-1, Karl Storz D-Light C photodynamic diagnostic (PDD)
Drug · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jul 21, 2026, 11:01 AM EDT
Terminated Phase 2 Interventional

Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy

NCT00073970
View directory record Official record
Conditions
Prostate Cancer
Interventions
celecoxib
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 22, 2012 · Synced Jul 21, 2026, 11:01 AM EDT
Recruiting Phase 2 Interventional

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

NCT04175431
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Positron Emission Tomography, Lymphadenectomy, Radiation Therapy, Abiraterone Acetate, Prednisone, Computed Tomography, Abiraterone, PSMA PET Scan
Procedure · Radiation · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2037
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 21, 2026, 11:01 AM EDT
Terminated Phase 3 Interventional Results available

Muscadine Plus (MPX) In Men With Prostate Cancer

NCT03535675
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
Muscadine Plus, Placebos
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
13
States / cities
Duarte, California • La Jolla, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Jul 21, 2026, 11:01 AM EDT
Not yet recruiting Phase 2 Interventional

Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

NCT07574541
View directory record Official record
Conditions
Adenocarcinoma, Prostate Cancer, Neoplasms, Carcinoma, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type
Interventions
TriAdeno vaccine, N-803
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 2Phase 3 Interventional Results available

68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment

NCT02673151
View directory record Official record
Conditions
Prostate Adenocarcinoma, PSA Failure, Recurrent Prostate Carcinoma
Interventions
Computed Tomography (CT) scan, 68Ga-PSMA-11, Positron Emission Tomography (PET)
Procedure · Drug
Lead sponsor
Andrei Iagaru
Other
Eligibility
18 Years and older · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Jul 21, 2026, 11:01 AM EDT
Terminated Phase 1 Interventional

First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer

NCT04077021
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Adenocarcinoma
Interventions
CCW702
Drug
Lead sponsor
Calibr, a division of Scripps Research
Other
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
San Diego, California • Baltimore, Maryland • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 3 Interventional

Comparison of Two Radiation Therapy Regimens in Treating Patients With Stage II or Stage III Prostate Cancer

NCT00062309
View directory record Official record
Conditions
Prostate Cancer
Interventions
radiation therapy
Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Not applicable Interventional

Prostate Conformal Cryotherapy

NCT00877682
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cryoablation
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Jul 21, 2026, 11:01 AM EDT
Active, not recruiting Phase 2 Interventional

Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

NCT02703623
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Abiraterone Acetate, Apalutamide, Cabazitaxel, Carboplatin, Ipilimumab, Laboratory Biomarker Analysis, Prednisone
Drug · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
3
States / cities
Houston, Texas • Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 21, 2026, 11:01 AM EDT
Terminated Phase 1 Interventional

Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer

NCT03829930
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Entinostat, Enzalutamide
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 1, 2021 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 2 Interventional

G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer

NCT02381236
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
G-202
Drug
Lead sponsor
GenSpera, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Jul 21, 2026, 11:01 AM EDT
Terminated Phase 1 Interventional

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

NCT04249947
View directory record Official record
Conditions
Prostatic Neoplasms, Castration-Resistant, Neoplasms by Histologic Type, Neoplasms, Prostate, Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Neoplasms, Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplasms by Site, Prostatic Disease, Salivary Gland Cancer, Salivary Gland Tumor, Adenoid Cystic Carcinoma, Salivary Duct Carcinoma, Mucoepidermoid Carcinoma, Acinic Cell Tumor
Interventions
P-PSMA-101 CAR-T cells, Rimiducid
Biological · Drug
Lead sponsor
Poseida Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
10
States / cities
Duarte, California • San Diego, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2025 · Synced Jul 21, 2026, 11:01 AM EDT
Terminated Phase 2 Interventional Results available

Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones

NCT04616547
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Questionnaire Administration, Tin Sn 117m Pentetate
Other · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Jul 21, 2026, 11:01 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

NCT05498272
View directory record Official record
Conditions
Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation, Prostatic Adenocarcinoma, High-Risk Cancer
Interventions
Olaparib, LHRH agonist
Drug
Lead sponsor
Rana McKay, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
La Jolla, California • Baltimore, Maryland • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 21, 2026, 11:01 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT04704505
View directory record Official record
Conditions
Prostate Adenocarcinoma, Metastatic Prostate Adenocarcinoma, Castration-resistant
Interventions
radium-223, Bipolar Androgen Therapy (BAT)
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jul 21, 2026, 11:01 AM EDT
Withdrawn Not applicable Interventional

Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients

NCT05156372
View directory record Official record
Conditions
Prostate Cancer Metastatic, Castrate Resistant Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Adenocarcinoma
Interventions
High Intensity Interval Training
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2024 · Synced Jul 21, 2026, 11:01 AM EDT